Current Issue March 2012, Vol. 36, No. 3

Issue Highlights

Invited Review

What do kinase inhibition profiles tell us about tyrosine kinase inhibitors used for the treatment of CML?
March 2012(Vol. 36 | No. 3 | Pages 253-261)
Michael W. Deininger, Paul Manley

Meeting Report

Update on developments in the diagnosis and prognostic evaluation of patients with myelodysplastic syndromes (MDS): Consensus statements and report from an expert workshop
March 2012(Vol. 36 | No. 3 | Pages 264-270)
Uwe Platzbecker, Valeria Santini, Ghulam J. Mufti, Claudia Haferlach, Jaroslaw P. Maciejewski, Sophie Park, Francesc Solé, Arjan A. van de Loosdrecht, Detlef Haase

Clinical Studies

Imatinib mesylate at therapeutic doses has no impact on folliculogenesis or spermatogenesis in a leukaemic mouse model
March 2012(Vol. 36 | No. 3 | Pages 271-274)
Beate Schultheis, Bart A. Nijmeijer, H. Yin, Roger G. Gosden, Junia V. Melo

Rare tetraploidy with large 5q deletion in acute myeloid leukemia with myelodysplasia-related changes (AML-MRC)
27 January 2012
Marie Jarosova, Radka Nedomova, Jaromir Hubacek, Milena Holzerova, Pavla Mickova, Beata Katrincsakova, Zuzana Pikalova, Tomas Papajik, Karel Indrak
In 2008, the World Health Organization (WHO) revised its classification of hematopoietic neoplasms and new “acute myeloid leukemia with myelodysplasia-related changes (AML-MRC)” was defined as “AML ar...
The Hans algorithm is not prognostic in patients with diffuse large B-cell lymphoma treated with R-CHOP
27 January 2012
Jorge J. Castillo, Brady E. Beltran, Moo-Kon Song, Ivana Ilic, Sirpa Leppa, Heidi Nurmi, Ritsuko Seki, Silvia Uccella, Jun-Min Li, Diana O. Treaba, Dariusz Stachurski, James N. Butera
Abstract: Our objective was to evaluate the non-germinal center (GC) profile as a marker for response and survival in DLBCL and to compare the characteristics of patients with GC and non-GC DLBCL trea...
A combination of thalidomide and arsenic trioxide is effective and well tolerated in patients with myelodysplastic syndromes
27 January 2012
Wei Wei, Fan Zhou, Yizi Zhang, Lieping Guo, Haotian Shi, Jian Hou
Abstract: Twenty-two patients with myelodysplastic syndromes (MDS) were treated with thalidomide plus arsenic trioxide (ATO). Twenty-two MDS patients receiving supportive care were used as controls. T...
Isolation of siRNA target by biotinylated siRNA reveals that human CCDC12 promotes early erythroid differentiation
24 January 2012
Cuiqing Fan, Lin Dong, Ning Zhu, Yuan Xiong, Jiewen Zhang, Le Wang, Yan Shen, Xiaoyin Zhang, Meihong Chen
Abstract: Erythroid differentiation is a tightly regulated multi-step process that has not been fully elucidated. We previously reported that a siRNA screened from random siRNA library, siRNA clone-67...
The minimal residual disease concept coming of age – Now for the direct comparison of methodologies
20 January 2012
Hans Beier Ommen, Anne Stidsholt Roug, Peter Hokland
The concept of minimal residual disease (MRD) and its translational and clinical implications is rapidly gaining recognition as one of the novel paradigms in the follow-up of cancer patients . Thus, t...

View More Articles in Press...

Prognostic significance of serum immunoglobulin paraprotein in patients with chronic lymphocytic leukemia
August 2011 (Vol. 35 | No. 8 | Pages 1060-1065)
Wei Xu, Yin-Hua Wang, Lei Fan, Cheng Fang, Dan-Xia Zhu, Dong-Mei Wang, Chun Qiao, Yu-Jie Wu, Jian-Yong Li
Can grapefruit juice decrease the cost of imatinib for the treatment of chronic myelogenous leukemia?
January 2011 (Vol. 35 | No. 1 | Pages e11-e12)
Shun-ichi Kimura, Shinichi Kako, Hidenori Wada, Kana Sakamoto, Masahiro Ashizawa, Miki Sato, Kiriko Terasako, Misato Kikuchi, Hideki Nakasone, Shinya Okuda, Rie Yamazaki, Kumi Oshima, Junji Nishida, Takuro Watanabe, Yoshinobu Kanda
- Full Text
- PDF (95 KB)
Alloreactive natural killer cells in hematopoietic stem cell transplantation
January 2011 (Vol. 35 | No. 1 | Pages 14-21)
Hollie J. Pegram, David S. Ritchie, Mark J. Smyth, Andres Wiernik, H. Miles Prince, Phillip K. Darcy, Michael H. Kershaw
Characteristics and outcome of myelodysplastic syndromes (MDS) with isolated 20q deletion: A report on 62 cases
July 2011 (Vol. 35 | No. 7 | Pages 863-867)
Thorsten Braun, Stéphane de Botton, Anne-Laure Taksin, Sophie Park, Odile Beyne-Rauzy, Valérie Coiteux, Rosa Sapena, Anne Lazareth, Geneviève Leroux, Khaled Guenda, Bruno Cassinat, Michaela Fontenay, Norbert Vey, Agnès Guerci, François Dreyfus, Dominique Bordessoule, Aspasia Stamatoullas, Sylvie Castaigne, Christine Terré, Virginie Eclache, Pierre Fenaux, Lionel Adès
MPN-associated myelofibrosis (MPN-MF)
January 2011 (Vol. 35 | No. 1 | Pages 12-13)
R.A. Mesa, A. Green, G. Barosi, S. Verstovsek, J. Vardiman, R.P. Gale
- Full Text
- PDF (155 KB)

Most Read lists are compiled every quarter.

On the Cover

New Issue Alert

Free Trial Issue

Journal Ranking

Journal Access

Full-text articles are available from 1995 to the present. Access to abstracts is complimentary. Access to full text is limited to print subscribers. Register or login to:

Buy a Subscription Now

Activate Online Access

Publishing Information

Leukemia Research is published by Elsevier.

Access this journal onSciVerse ScienceDirect

About Leukemia Research

Leukemia Research an international journal which brings comprehensive and current information to all health care professionals involved in basic and (or) applied clinical research in leukemias, lymphomas, multiple myeloma and other hematologic malignancies. The editors encourage the submission of articles relevant to normal and leukemic hemopoiesis, biochemistry, cell biology, immunology and molecular biology as well as epidemiologic and clinical studies.

Specifically, of major interest will be articles that encompass the application of oncogenes, growth factors, cell markers, cell cycle and differentiation agents, novel therapeutics and clinical trials in both the acute and chronic leukemias as well as the myelodysplastic syndromes. In addition we solicit selected articles on the rapidly increasing specialty of marrow or stem cell reconstitution after high dose therapy with curative attempt in patients with a wide range of neoplasms.

MDS Foundation Information

The MDS Foundation is a multidisciplinary, international organization devoted to the prevention, treatment, and study of the myelodysplastic syndromes. The organization is based upon the premise that international cooperation will accelerate the process leading to the control and cure of these diseases.